The application for phase I trial of Reliance Life Sciences’ recombinant protein-based vaccine candidate will be reviewed by the Subject Expert Committee (SEC) on August 26.
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.